Zoetis shares drop 52% in 12 months but offer 50% upside with steady dividends and offsetting growth segments.
Zoetis, spun off from Pfizer in 2013, has seen its share price fall 52% over the past year, now trading at just 12 times trailing earnings. Despite slowing revenue growth of 3% in Q1 2026, growth in international and livestock segments is balancing w...
